E
Eric J. Sherman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 253
Citations - 10630
Eric J. Sherman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Radiation therapy. The author has an hindex of 44, co-authored 219 publications receiving 8049 citations. Previous affiliations of Eric J. Sherman include Kettering University & Fox Chase Cancer Center.
Papers
More filters
Journal ArticleDOI
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho,Ravinder K. Grewal,Rebecca Leboeuf,Eric J. Sherman,David G. Pfister,Désirée Deandreis,Keith S. Pentlow,Pat Zanzonico,Sofia Haque,Somali Gavane,Ronald Ghossein,Julio C. Ricarte-Filho,José Carlos de Miguel Domínguez,Ronglai Shen,R. Michael Tuttle,Steve Larson,James A. Fagin +16 more
TL;DR: Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease.
Journal ArticleDOI
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang,Qiang Zhang,David I. Rosenthal,Phuc Felix Nguyen-Tan,Eric J. Sherman,Randal S. Weber,James M. Galvin,James A. Bonner,Jonathan Harris,Adel K. El-Naggar,Maura L. Gillison,Richard C.K. Jordan,Andre Konski,Wade L. Thorstad,Andy Trotti,Jonathan J. Beitler,Adam S. Garden,William J. Spanos,Sue S. Yom,Rita Axelrod +19 more
TL;DR: Adding cetuximab to radiation-cisplatin did not improve outcome and hence should not be prescribed routinely, and the PFS and OS were higher in patients with p16-positive OPC, but outcomes did not differ by EGFR expression.
Journal ArticleDOI
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Ezra E.W. Cohen,Lee S. Rosen,Everett E. Vokes,Merrill S. Kies,Arlene A. Forastiere,Francis P. Worden,Madeleine A. Kane,Eric J. Sherman,Sinil Kim,Paul Bycott,Michael A. Tortorici,David R. Shalinsky,K. F. Liau,Roger B. Cohen +13 more
TL;DR: Axitinib is a selective inhibitor of VEGFR with compelling antitumor activity in all histologic subtypes of advanced thyroid cancer.
Journal ArticleDOI
Transoral robotic surgery: radical tonsillectomy.
TL;DR: Radical tonsillectomy using TORS is a new technique that offers excellent access for resection of carcinomas of the tonsil with acceptable acute morbidity and long-term oncologic and functional outcomes.
Journal ArticleDOI
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J. Wirth,Eric J. Sherman,Bruce G. Robinson,Benjamin Solomon,Hyunseok Kang,Jochen H. Lorch,Francis P. Worden,Marcia S. Brose,Jyoti D. Patel,Sophie Leboulleux,Yann Godbert,Fabrice Barlesi,John C. Morris,Taofeek K. Owonikoko,Daniel Shao-Weng Tan,Oliver Gautschi,Jared Weiss,Christelle De La Fouchardiere,Mark E. Burkard,Janessa Laskin,Matthew H. Taylor,Matthias Kroiss,Jacques Medioni,Jonathan W. Goldman,Todd M. Bauer,Benjamin Levy,Viola W. Zhu,Nehal Lakhani,Victor Moreno,Kevin Ebata,Michele Nguyen,Dana Heirich,Edward Y. Zhu,Xin Huang,L. Yang,Jennifer Kherani,S. Michael Rothenberg,Alexander Drilon,Vivek Subbiah,Manisha H. Shah,Maria E. Cabanillas +40 more
TL;DR: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment.